Details of the Drug
General Information of Drug (ID: DMQVUZP)
Drug Name |
2-(4-bromo-2-formylphenoxy)acetic acid
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
2-(4-bromo-2-formylphenoxy)acetic acid; 24589-89-7; (4-bromo-2-formylphenoxy)acetic acid; CHEMBL385009; AC1LJ5IQ; bromoformylphenoxyaceticacid; Oprea1_723931; AC1Q764A; SCHEMBL2879909; KS-00000LHU; CTK1A1564; DTXSID80359528; MolPort-000-886-040; KXRYNWDCFUKVNN-UHFFFAOYSA-N; ZINC586295; SP656; 4-bromo-2-formylphenoxyacetic acid; ALBB-007850; 4-bromo-2-formylphenoxy acetic acid; 2-formyl-4-bromophenoxy acetic acid; STK201324; SBB020100; BDBM50200251; BBL023190; 8265AD; AKOS000113320; MCULE-3263948503; AC-0818; RP14657; ACN-052850
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 259.05 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.7 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 4 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||